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Abstract
Background: Osteosarcoma is a malignant tumor with high ability to form invasion and metastasis. Identifying
prognostic factor in osteosarcoma is helpful to select those patients for more aggressive management. Our study
evaluated serum alkaline phosphatase (ALP) cooperating with matrix metalloproteinase-9 (MMP-9) as an important
prognostic predictor for local recurrence and distant metastasis of osteosarcoma.
Methods: 177 cases were included from the osteosarcoma patients treated at 1st Affiliated Hospital of Sun Yat-sen
University (1999-2008). Pre-chemotherapy serum ALP (pre-ALP) were studied and correlated with tumor recurrence,
lung metastasis and patient survival. MMP-9 protein in tumor tissues was detected by immunohistochemistry and
correlated with pre-ALP level.
Results: Pre-ALP were partitioned into normal, high, and very high groups, in each group the incidence of
metastases was 12.2%, 21.2% and 34.6%, respectively (p = 0.007). In the three groups the mean disease-free survival
(DFS) was 57 ± 3.15, 28 ± 3.57 and 14 ± 3.35 months, respectively (p < 0.001); overall survival (OS) was 92 ± 26.89,
39 ± 8.61 and 17 ± 5.07 months, respectively (p < 0.001). By multivariate analysis, elevated serum pre-ALP were
associated with shorter DFS (p = 0.018) and OS (p = 0.031). If elevated ALP levels decreased after clinical treatment,
the incidence of lung metastasis rate decreased (p = 0.028); DFS and OS were both prolonged (p < 0.001). Pre-ALP
was also positively correlated with MMP-9 expression (p = 0.015) in tumor tissue.
Conclusions: Pre-ALP was an independent prognostic factor for the survival of osteosarcoma patients in south
China, and correlated with MMP-9 expression and lung metastasis. ALP can also serve as a prognostic marker for
treatment, and merit large-scale validation studies.
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Background
Osteosarcoma is a malignant bone tumor that typically
occurs in children, adolescents and young adults. Incor-
poration of chemotherapy into initial treatment signifi-
cantly increased the cure rate. However, about 40% of
patients died from lung metastases [1]; it will be impor-
tant to develop biomarkers that can inform therapy
while offering prognostic insight, especially in identifying
poor prognosis patients who should be offered more
aggressive therapy at an early time point in the clinical
continuum [2-4].
Serum alkaline phosphatase (ALP) can be easily
demonstrated in osteosarcoma patients, which may be
predictive of survival [5-8]. However this remains con-
troversial [9]. Alkaline phosphatase has been addressed
as a prognostic factor by several authors with inconclu-
sive results. Only a few previous studies have studied
the ALP levels in osteosarcoma patients after che-
motherapy and surgery [10] or cases of local recurrence
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any medium, provided the original work is properly cited.or lung metastasis after surgery [11], or have considered
MMP-9 expression in these contexts [12-14]. Accord-
ingly, we examined whether or not serum ALP was pre-
dictive of lung metastasis, local recurrence and survival
after surgery of osteosarcoma patients in south China.
As known, MMP-9 expression and function is involved
during lung metastasis of tumor, so we concerned
whether serum ALP was connected with MMP-9
expression.
Methods
Patients and methods
The study population consisted of 177 patients who pre-
sented at 1st Affiliated Hospital of Sun Yat-sen Univer-
sity with primary non-metastatic osteosarcoma from
1999 to 2008. Methotrexate(MTX), cisplatin (DDP),
doxorubicin (ADM), ifosfamide (IFO) were using during
chemotherapy. All patients received neo-chemotherapy
followed by surgical resection and post-operative che-
motherapy (Figure 1); “standard” chemotherapy consist-
ing of 4 neo-chemotherapy courses and 8 or more post-
operative chemotherapy courses.
Fasting morning blood samples were collected at diag-
nosis, analyzed for pre-chemotherapy serum ALP (pre-
ALP). Because growth influences ALP expression [15],
150 U/L was considered as the upper normal serum
ALP limit in patients less than 18 years, and 110 U/L in
those 18 years or older. Pre-ALP values were divided
into three categories: normal (below the upper normal
limit), high (elevated to less than twice the upper limit),
and very high (elevated more than twice the upper
limit).
MMP-9 Immunohistochemistry
Tumor biopsy samples from these patients (n = 97)
were cut into 4 μm thick serial tissue sections. Sections
were deparaffined in xylene and rehydrated in grade
alcohols. The sections were then treated with 3% hydro-
gen peroxide for 30 min to quench the endogenous per-
oxidase activity. Antigenic retrieval was performed by
submerging in citric acid (pH = 6.0) and microwaving.
The slides were then allowed to cool at room tempera-
ture. The sections were then incubated with primary
antibodies for MMP-9 (mouse monoclonal, MAB-0245,
maixin Biological Technology, Fuzhou) overnight at 4°C;
phosphate-buffered saline (PBS) was used as negative
control. After washing with PBS at room temperature,
goat anti-mouse antibody conjugated to a horseradish
peroxidase decorated dextran polymer backbone (Envi-
sion, Dako, Denmark), was applied for 30 min at 37°C.
Staining was carried out with 3, 3’-diaminobenzidine tet-
rahydrochloride. Mayer’s hematoxylin was applied as a
counter stain.
Each section was evaluated by three independent
pathologists without knowledge of the clinical case fea-
tures. We selected 100 cells from each of 5 fields and
evaluated for MMP-9 positivity. Staining results were
scored semiquantitatively based on the combined per-
centage (five-tiered algorithm [0: 0% positive cells; 1: <
25% positive cells; 2: 25%-50% positive cells; 3: 56%-75%
Figure 1 The chemotherapeutic agents and the treatment protocol of 177 osteosarcoma patients.
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cytoplasmic staining (four-tiered system [0: negative; 1:
weak; 2: moderate; 3: strong]), then tabulated as an
MMP-9 expression index (percentage positive) × (inten-
sity)[16,17]. The indexes separately from all the three
pathologists were averaged as the final MMP-9 expres-
sion index.
Statistical analysis
Disease-free survival (DFS) was calculated as time from
the date of diagnosis to the date of first local recurrence
or metastatic failure after surgery or to the date of last
follow-up in patients without recurrence or metastasis.
Overall survival (OS) was calculated as the time from
the date of diagnosis to the date of death or the date of
last follow-up if the patient was still alive. Survival rate
was calculated using the Kaplan-Meier method. Univari-
ate and multivariate survival analyses were performed to
test the association of clinicopathological features with
DFS and OS, incorporating log-rank testing and Cox
proportional hazard regression models. Correlations
between pre-ALP and clinicopathological features were
examined by chi-square or ANOVA testing. Pearson
analyses were used to test correlations between pre-ALP
and MMP-9 expression in osteosarcoma tissues. Statisti-
cal analyses were conducted using SPSS 16.0 (SPSS, Inc.,
Chicago, IL, USA) with a 2-sided significance level of P
< 0.05.
Results
Patient clinical characteristics
Primary osteosarcoma patients with no metastasis at
diagnosis (n = 177) were analyzed; 117 male and 60
female patients. The median age was 18.73 years
(range: 6-56 years); 72 patients were older than 18
years of age. Tumors were located in the femur (93/
177), tibia (52/177), fibula (13/177), humerus (12/177),
radius (1/177) and other sites (6/177). Histological sub-
types included 109 osteoblastic, 25 chondroblastic, 16
fibroblastic, 11 dilated blood vessel and 16 miscella-
neous osteosarcoma subtypes. Limb sparing surgery
was performed in 92 patients whereas 85 underwent
amputation.
The median follow-up was 87 months (range: 8-144
months). During follow-up 40 (22.6%) and 14 (7.9%)
patients had lung metastases and local recurrence,
respectively. The lung metastasis and/or local recur-
rence were diagnosed by both imaging and pathology.
The median OS and DFS of patients were 28 months
(95% confidence interval [CI], 32.84-41.95 months) and
24 months (95% CI, 27.79-36.84 months), respectively;
96 patients died of tumor-related causes during the
study.
Correlation between pre-ALP and clinicopathologic
characteristics
As shown in Table 1, of the 40 patients who developed
lung metastasis, 6 cases were in the normal pre-ALP, 16
cases were in the high pre-ALP, and 18 cases were in
the very high pre-ALP groups; while the rates of lung
metastasis in the three groups were 12.2%, 21.2% and
34.6%, respectively (p = 0.007). It showed that pre-ALP
levels were positively correlated with lung metastasis.
Moreover, pre-ALP levels were inversely related to
tumor size and courses of post-operative chemotherapy.
Pre-ALP levels were significantly elevated in osteoblastic
subtype than in other subtypes, also in femur sites than
in other sites (p < 0.01, respectively). No correlation
between pre-ALP levels and local recurrence was
demonstrable.
The possible correlation between pre-ALP levels and
osteosarcoma MMP-9 expression was examined. Immu-
nohistochemistry staining showed that MMP-9 proteins
were mainly expressed in tumor cytoplasm and posi-
tively correlated with elevated pre-ALP levels (r = 0.250,
p = 0.015; Figure 2). The expression of MMP-9 was sig-
nificantly higher in the very high pre-ALP group com-
pared to the high or normal pre-ALP groups (p =
0.034).
Pre-ALP is associated with an improved prognosis
Next in order to elucidate the possible relationship
between pre-ALP levels and patient survival, we demon-
strated a positive correlation with decreased DFS and
OS. The DFS was 57 ± 3.15 months in the normal pre-
ALP group, 28 ± 3.57 months in high pre-ALP group,
and 14 ± 3.35 months in very high pre-ALP group,
respectively (Figure 3a-b; p < 0.001). Furthermore, OS
was 92 ± 26.89, 39 ± 8.61 and 17 ± 5.07 months in
these same three pre-ALP groups, respectively (p <
0.001). The survival rate was 65.3% (32/49) for patients
with normal pre-ALP, while they dramatically dropped
to 46.1% (35/76) and 26.9% (14/52) for patients with
high pre-ALP and very high pre-ALP, respectively
(Table 1; p < 0.01). We also considered whether pre-
ALP levels could serve as a prognostic factor regardless
of therapeutic approaches. Pre-ALP levels correlated
strongly with patient survival even after stratifying for
types of surgery, courses of post-chemotherapy, and
incidence of lung metastasis or local recurrence (Figure
4a-h).
Given the seeming responsiveness of serum ALP to
osteosarcoma clinical treatment [18], we analyzed the
ALP level after clinical treatment. If elevated pre-ALP
levels decreased after clinical treatment, the incidence of
lung metastasis was 28.2% (22/78; p = 0.028) and DFS
and OS were 24 ± 5.00 and 32 ± 7.86 months,
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metastasis was 40.0% (10/25), and DFS and OS were 10
± 1.87 and 19 ± 3.30 months, respectively (Figure 3c-d).
The decrease of pre-ALP was not correlated with local
recurrence.
Analyses of Relative Risk indicate the role of pre-ALP in
the prognosis of primary osteosarcoma
We examined DFS and OS using Cox regression hazard
analyses to determine whether pre-ALP levels could
serve as a clinically useful prognostic assessment factor
in osteosarcoma. Univariate Cox regression analyses
revealed that elevated pre-ALP levels were associated
with inferior survival in primary osteosarcoma patients
(Table 2; p < 0.01). The relative risk indicated that
osteoblastic osteosarcoma, tumor size ≥ 6 cm, amputa-
tion, post-operative chemotherapy not standard, lung
metastasis and local recurrence were all worse predic-
tors. After adjusting for potential confounding factors,
elevated pre-ALP in osteosarcoma was found to be a
poorer survival predictor for DFS and OS in an indepen-
dent manner (p = 0.018 and 0.031, respectively; Table
3). Using multivariate Cox regression model for clinical-
pathologic diagnoses gave rise to the following results:
amputation and lung metastasis predicted poorer DFS.
Osteoblastic osteosarcoma, tumor size ≥ 6c m ,
Table 1 Correlation between pre-ALP and clinicopathologic characteristics
Clinicopathologic characteristics Very high pre-ALP
(n = 52)
High pre-ALP
(n = 76)
Normal pre-ALP
(n = 49)
P value
Gender
Male 35 50 32 0.831
Female 17 26 17
Primary location
Humerus 6 2 4 0.005
Radius 0 1 0
Femur 36 40 17
Tibia 7 28 17
Fibula 3 2 8
Others 0 3 3
Histological type
Osteoblastic 40 45 24 < 0.01
Chondroblastic 8 12 5
Fibroblastic 1 9 6
Dilated blood vessels 3 5 3
Others 0 5 11
Tumor size
< 6 cm 14 35 26 0.008
≥ 6c m 3 8 4 1 2 3
Surgery type
Amputation 24 35 26 0.268
Limb sparing 28 41 23
Post-operative chemotherapy
No standard
a 40 54 20 < 0.01
Standard
b 12 22 29
Lung metastasis
Yes 18 16 6 0.007
No 34 60 43
Local recurrence
Yes 4 7 3 0.782
No 48 69 46
Survival status
Alive 14 35 32 < 0.01
Dead 38 41 17
ALP alkaline phosphatase
a post-operative chemotherapy cycles < 8
b post-operative chemotherapy cycles ≥ 8
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The relative risk showed no obvious differences when
including other clinicopathologic features such as gen-
der, primary location and local recurrence in the ana-
lyses using the multivariate Cox regression model.
Discussion
Osteosarcoma is characterized by the production of
osteoid tissue or immature bone [19]. Biochemical mar-
kers which reflect global skeletal activity are sensitive
indicators of early bone metabolism disturbances.
Among them, products of the osteoblastic cells activity,
serum alkaline phosphatase (ALP) which is one of the
markers of bone formation is considered to be clinically
useful [5]. Some authors had proved that serum ALP
was raised in osteosarcoma patients and predicted a
poorer survival [20,21]. Other authors have also
reported the most important poor prognostic factor for
survival was elevated ALP at diagnosis [5,22,23]. It
appeared that ALP was a prognostic factor in multivari-
ate analysis [24].
As known, serum levels of ALP are greater in infants
and children than in adults [15]. Peak values occur at
puberty, perhaps due to high skeletal growth velocity
and rapid bone turnover during this period [25,26].
However, all the studies before [8,26,27] do not stratify
for these differences, so the effect of age on ALP levels
can not be evaluated. In our study, the age of patients
ranged from 6 years to 56 years. To minimizing the
influence of age on serum ALP levels, we defined upper
normal limit of the serum ALP in patients younger than
18 years is 150 U/L and older than 18 years as 110 U/L.
For the first time, we divided pre-ALP into three groups
based on different normal upper limit. This method
focused on the relationship between the quantity of the
changes of ALP and the prognosis of the patients, not
Figure 2 Immunohistochemical analyses of MMP-9 staining (a: negatives, × 200; b: weak staining, x200; c: moderate staining, × 200;
d: strong staining, × 200). As can be seen, MMP-9 shows strongest staining in very high pre-ALP group of primary osteosarcoma tissues (e).
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play the relationship between ALP and other clinical
features much more correctly than the ALP (yes/no)
grouping.
With effective chemotherapy or surgery for osteosar-
coma patients, the decrease of the tumor cells in osteosar-
coma patients caused the process of pathological
osteogenesis slow down [28]. In our study, all the patients
received neo-adjuvant chemotherapy, surgery and post-
operative chemotherapy. We found that the patients
whose elevated pre-ALP decreased after chemotherapy
had significantly longer DFS and OS than the patients
whose pre-ALP did not decrease following treatment.
Decrease of serum ALP during clinical treatment may
indicate low osteoblastic activity and insufficient minerali-
zation, and also it may be a symptom of a positive reaction
to treatment and disease remission. Thus, the change of
serum ALP can be used as the marker for the response to
clinical treatment in osteosarcoma patients. It should be
helpful to evaluate the efficacy of different therapeutic pro-
tocols and plan new more aggressive therapeutic strategy.
Bramer [18] has found similar results, but the limitation
w a st h a to n l yp a t i e n t so v e rt h ea g eo f1 8w e r es t u d i e d ,
making their results only valid for adults, whereas the
majority of osteosarcoma patients are under the age of 18.
M o r e o v e r ,t h e yd i dn o te x a m i n et h ep r e d i c t i v ef a c t o r s
using multivariate Cox regression analysis.
Zhang, et al [29] and Hsieh, et al [11] have shown that
released serum ALP was not only correlated with survi-
val, but also with the recurrence and metastasis in
osteosarcoma patients. Our study has pointed out the
similar view on the correlationship between serum ALP
and metastasis. While because there were so few
patients with local recurrence in each pre-ALP group,
we could not find the positive relationship between
serum ALP and local recurrence. Moreover, we exam-
ined the MMP-9 expression levels in different pre-ALP
groups. There was a significant correlation between the
expression of MMP-9 and pre-ALP in these osteosar-
coma samples. The positive rate and index of MMP-9
expression in osteosarcoma tissues were highest in very
high pre-ALP group. The patients with high level of
serum ALP at diagnosis had much higher risk of lung
metastasis. Osteosarcoma metastasis is associated with
the infiltration and expansion of tumor cells, which
leading to the activation of osteoclasts. The activation of
osteoclasts increased the severity of osteolysis accompa-
nying with elevated ALP [30,31]. Meanwhile, the matrix
metalloproteinases (MMPs) can be secreted by the can-
cer cell to dissolve extracellular matrix, which may have
an interaction with elevated ALP. Therefore, to improve
the DFS, pre-ALP would be helpful to identify patients
with a poor prognosis who could be treated with more
aggressive therapy.
Figure 3 Influence of serum ALP levels on Disease-free survival (DFS) and Overall survival (OS) Kaplan-Meier curves shows that the
patients with high pre-ALP levels have poorer DFS(a) and OS (b); with pre-ALP decreased after clinical treatment have better DFS (c)
and OS (d); all of them have significant difference(p < 0.05).
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Page 6 of 10Figure 4 Overall survival curves were stratified by pre-ALP levels according to surgery style, Post-chemotherapy, metastasis and local
recurrence after surgery. Kaplan-Meier curves shows that the patients with high pre-ALP levels have poorer OS independent of surgery type
(a, b), Post-chemotherapy (c, d), metastasis (e, f) and local recurrence after surgery (g, h).
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Clinical characteristics OS DFS
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Histological type
Osteoblastic 4.090(1.491,11.251) 0.006 3.524(1.283,9.677) 0.015
Chondroblastic 2.741(0.882,8.521) 0.081 2.140(0.689,6.648) 0.188
Fibroblastic 1.573(0.422,5.862) 0.500 1.231(0.331,4.588) 0.756
Dilated blood vessels 3.313(0.933,11.767) 0.064 3.249(0.913,11.555) 0.069
Others 1.000 1.000
Tumor size
< 6 cm 1.000 1.000
≥ 6 cm 2.112(1.374,3.246) 0.001 1.968(1.282,3.020) 0.002
Surgery type
Amputation 1.000 1.000
Limb sparing 0.439(0.292,0.660) < 0.01 0.501(0.333,0.753) 0.001
Post-operative chemotherapy
Not standard
a 1.000 1.000
Standard
b 0.612(0.390,0.960) 0.033 0.646(0.412,1.013) 0.057
Pre-ALP
Normal 1.000 1.000
High 1.938(1.099,3.418) 0.022 1.985(1.126,3.500) 0.018
Very high 3.402(1.915,6.044) < 0.01 3.267(1.840,5.800) < 0.01
Lung metastasis
No 1.000 1.000
Yes 2.380(1.531,3.698) < 0.01 5.562(3.422,9.040) < 0.01
Local recurrence
No 1.000 1.000
Yes 1.255(0.652,2.418) 0.496 2.274(1.168,4.427) 0.016
OS overall survival, DFS disease-free survival, ALP alkaline phosphatase, CI confidence interval
a post-operative chemotherapy cycles < 8
b post-operative chemotherapy cycles ≥ 8
Table 3 Multivariate Cox regression analysis of potential prognostic factors for 177 osteosarcoma patients
Clinical characteristics OS DFS
Hazard ratio (95% CI ) P Hazard ratio (95% CI ) P
Histological type
Osteoblastic 3.615(1.232,10.603) 0.019 2.653(0.915,7.693) 0.072
Chondroblastic 2.262(0.673,7.602) 0.187 1.449(0.439,4.781) 0.543
Fibroblastic 1.670(0.425,6.564) 0.463 1.093(0.285,4.198) 0.897
Dilated blood vessels 3.506(0.932,13.195) 0.064 3.950(1.061,14.773) 0.041
Others 1.000 1.000
Tumor size
< 6 cm 1.000 —— ——
≥ 6 cm 1.685(1.071,2.650) 0.024
Surgery type
Amputation 1.000 1.000
Limb sparing 0.375(0.247,0.570) < 0.01 0.392(0.257,0.597) < 0.01
Pre-ALP
Normal 1.000 1.000
High 1.461(0.806,2.647) 0.212 1.542(0.847,2.806) 0.157
Very high 1.979(1.063,3.684) 0.031 2.090(1.135,3.848) 0.018
Lung metastasis
No 1.000 1.000
Yes 2.232(1.395,3.572) 0.001 5.456(3.266,9.114) < 0.01
OS overall survival, DFS disease-free survival, ALP alkaline phosphatase, CI confidence interval
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and difficulty in interpreting the true prognostic effect of
many of the variables evaluated [8,32]. Few studies have a
look at whether serum ALP is equally pertinent in differ-
ent therapeutic populations. In contrast, our study found
it remained true that pre-ALP was strongly correlated
with the survival of osteosarcoma patients even after stra-
tifying the patients based upon surgery type, post-che-
motherapy cycles, lung metastasis and local recurrence.
Conclusions
In summary, the current study demonstrates the level of
ALP is an independent prognostic factor for the survival
of osteosarcoma patients, and is correlated with MMP-9
expression in osteosarcoma tissues. The ALP measured
at diagnosis, or after clinical treatment and the change
of ALP after treatment are possible valuable factors in
predicting the clinical treatment response, lung metasta-
sis and survival in osteosarcoma. Identifying ALP would
be helpful in predicting the chance of metastasis and
survival, especially early in treatment.
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